<DOC>
	<DOCNO>NCT00943839</DOCNO>
	<brief_summary>RATIONALE : Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This clinical trial study well sunitinib malate work treat patient kidney cancer .</brief_summary>
	<brief_title>Sunitinib Malate Treating Patients With Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether link exist effectiveness therapy sunitinib malate development blood biomarkers , specifically angiogenic factor VEGF interleukin-8 ( IL-8 ) , patient kidney cancer . Secondary - To evaluate link time progression development VEGF IL-6 CXCL7 CXCK5 blood level patient . - To evaluate link VEGF IL-6 CXCL7 CXCK5 blood level disease-free survival patient 3 , 6 , 9 , 12 month treatment . - To evaluate link VEGF IL-6 CXCL7 CXCK5 blood level overall survival patient . OUTLINE : This multicenter study . Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Blood sample collect baseline every 6 week pharmacokinetic analysis .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Metastatic disease require firstline treatment sunitinib malate No prior therapy metastatic disease No symptomatic uncontrolled cerebral metastasis PATIENT CHARACTERISTICS : Affiliation French Social insurance Life expectancy â‰¥ 3 month No heart failure No chronic unstable disease No long QT interval No history another primary cancer No severe , uncontrolled acute infection No severe , uncontrolled hypertension No psychological disorder PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>